Chung LW - Search Results

1

Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.

Ko SC, Gotoh A, Thalmann GN, Zhau HE, Johnston DA, Zhang WW, Kao C, Chung LW. Ko SC, et al. Among authors: chung lw. Hum Gene Ther. 1996 Sep 10;7(14):1683-91. doi: 10.1089/hum.1996.7.14-1683. Hum Gene Ther. 1996. PMID: 8886839

2

Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.

Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, Kao C, Lim SD, Amin MB, Yang H, Black ME, Matsubara S, Nakagawa M, Gillenwater JY, Zhau HE, Chung LW. Kubo H, et al. Among authors: chung lw. Hum Gene Ther. 2003 Feb 10;14(3):227-41. doi: 10.1089/10430340360535788. Hum Gene Ther. 2003. PMID: 12639303 Clinical Trial.

3

A fetal rat urogenital sinus mesenchymal cell line (rUGM): accelerated growth and conferral of androgen-induced growth responsiveness upon a human bladder cancer epithelial cell line in vivo.

Zhau HE, Hong SJ, Chung LW. Zhau HE, et al. Among authors: chung lw. Int J Cancer. 1994 Mar 1;56(5):706-14. doi: 10.1002/ijc.2910560516. Int J Cancer. 1994. PMID: 7508897

4

Biomarkers associated with prostate cancer progression.

Zhau HE, Pisters LL, Hall MC, Zhao LS, Troncoso P, Pollack A, Chung LW. Zhau HE, et al. Among authors: chung lw. J Cell Biochem Suppl. 1994;19:208-16. J Cell Biochem Suppl. 1994. PMID: 7529853 Review.

5

Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Thalmann GN, et al. Among authors: chung lw. Cancer Res. 1994 May 15;54(10):2577-81. Cancer Res. 1994. PMID: 8168083

6

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW. Thalmann GN, et al. Among authors: chung lw. J Natl Cancer Inst. 1996 Jun 19;88(12):794-801. doi: 10.1093/jnci/88.12.794. J Natl Cancer Inst. 1996. PMID: 8637045

7

Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model.

Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP, Chung LW, Visakorpi T. Hyytinen ER, et al. Among authors: chung lw. Br J Cancer. 1997;75(2):190-5. doi: 10.1038/bjc.1997.32. Br J Cancer. 1997. PMID: 9010025 Free PMC article.

8

Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers.

Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW. Gotoh A, et al. Among authors: chung lw. J Urol. 1997 Aug;158(2):636-41. J Urol. 1997. PMID: 9224383

9

Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.

Cheon J, Ko SC, Gardner TA, Shirakawa T, Gotoh A, Kao C, Chung LW. Cheon J, et al. Among authors: chung lw. Cancer Gene Ther. 1997 Nov-Dec;4(6):359-65. Cancer Gene Ther. 1997. PMID: 9408606

10

Human prostate cancer progression models and therapeutic intervention.

Chung LW, Kao C, Sikes RA, Zhau HE. Chung LW, et al. Hinyokika Kiyo. 1997 Nov;43(11):815-20. Hinyokika Kiyo. 1997. PMID: 9436028 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

430 results

Search Page

Filters